CY1112327T1 - Θεραπευτικοι ρετροϊικοι φορεις για γονιδιακη θεραπεια - Google Patents
Θεραπευτικοι ρετροϊικοι φορεις για γονιδιακη θεραπειαInfo
- Publication number
- CY1112327T1 CY1112327T1 CY20101100906T CY101100906T CY1112327T1 CY 1112327 T1 CY1112327 T1 CY 1112327T1 CY 20101100906 T CY20101100906 T CY 20101100906T CY 101100906 T CY101100906 T CY 101100906T CY 1112327 T1 CY1112327 T1 CY 1112327T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gene therapy
- retrophytical
- retiring
- gender
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
Abstract
Αποκαλύπτονται ρετροϊικοί φορείς γονιδιακής θεραπείας που βελτιστοποιούνται για την ειδική ερυθροειδών έκφραση και την αντιμετώπιση των καταστάσεων αιμοσφαιρινοπάθειας.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43332102P | 2002-12-13 | 2002-12-13 | |
US47582203P | 2003-06-04 | 2003-06-04 | |
US51331203P | 2003-10-21 | 2003-10-21 | |
EP03813391A EP1581056B1 (en) | 2002-12-13 | 2003-12-11 | Therapeutic retroviral vectors for gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112327T1 true CY1112327T1 (el) | 2015-12-09 |
Family
ID=32600914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100906T CY1112327T1 (el) | 2002-12-13 | 2010-10-11 | Θεραπευτικοι ρετροϊικοι φορεις για γονιδιακη θεραπεια |
Country Status (9)
Country | Link |
---|---|
US (6) | US7901671B2 (el) |
EP (1) | EP1581056B1 (el) |
AT (1) | ATE474460T1 (el) |
AU (1) | AU2003296958A1 (el) |
CY (1) | CY1112327T1 (el) |
DE (1) | DE60333487D1 (el) |
ES (1) | ES2348868T3 (el) |
HK (1) | HK1082379A1 (el) |
WO (1) | WO2004054512A2 (el) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE474460T1 (de) | 2002-12-13 | 2010-08-15 | Genetix Pharmaceuticals Inc | Therapeutische retrovirus-vektoren für gentherapie |
WO2007109583A2 (en) | 2006-03-17 | 2007-09-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
US20090144270A1 (en) * | 2007-11-29 | 2009-06-04 | Jack Thacher Leonard | Methods for the prevention of diseases |
GB0812191D0 (en) * | 2008-07-03 | 2008-08-13 | Greater Glasgow Health Board | Modified cells and methods of monitoring their viability |
ES2631458T3 (es) | 2010-03-04 | 2017-08-31 | Interna Technologies B.V. | Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT |
CA2804599C (en) | 2010-07-06 | 2023-01-31 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
CA2838749A1 (en) | 2011-06-10 | 2012-12-13 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
US9783822B2 (en) | 2011-09-23 | 2017-10-10 | Bluebird Bio, Inc. | Gene therapy methods |
MX359398B (es) | 2011-09-30 | 2018-09-27 | Bluebird Bio Inc | Compuestos para transduccion viral mejorada. |
ES2688619T3 (es) | 2011-12-22 | 2018-11-05 | Interna Technologies B.V. | MiARN para tratar el cáncer de cabeza y de cuello |
US20150118265A1 (en) * | 2012-03-13 | 2015-04-30 | Anthrogenesis Corporation | Modified erythrocyte precursor cells and uses thereof |
WO2014043131A1 (en) * | 2012-09-14 | 2014-03-20 | The Regents Of The University Of California | Lentiviral vector for stem cell gene therapy of sickle cell disease |
WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
PT3502240T (pt) | 2012-11-27 | 2021-08-11 | Childrens Medical Ct Corp | Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal |
AU2014348683B2 (en) | 2013-11-18 | 2020-11-05 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
RU2736495C2 (ru) | 2014-04-01 | 2020-11-17 | Рубиус Терапьютикс, Инк. | Способ и композиции для иммуномодуляции |
BR112016024565A2 (pt) | 2014-04-25 | 2018-01-23 | Children's Medical Center Corporation | composições e métodos de tratar hemoglobinopatias |
EP3186395B2 (en) * | 2014-08-26 | 2023-03-29 | The Board of Trustees of the Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
CA2957737A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
EP3191596B1 (en) | 2014-09-11 | 2019-10-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Lentiviral vector for treating hemoglobin disorders |
EP3247409B1 (en) * | 2015-01-21 | 2020-11-04 | Cornell University | Viral vectors for prophylaxis and therapy of hemoglobinopathies |
ES2835861T3 (es) | 2015-05-08 | 2021-06-23 | Childrens Medical Ct Corp | Direccionamiento de regiones funcionales del potenciador de BCL11A para la reinducción de hemoglobina fetal |
GB201600328D0 (en) | 2016-01-08 | 2016-02-24 | Univ Oslo Hf | Anti-CD37 chimeric antigen receptors and immune cells expressing them |
WO2017139561A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
MX2018009750A (es) | 2016-02-12 | 2019-02-07 | Bluebird Bio Inc | Composiciones potenciadoras de vcn y métodos para su uso. |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
WO2018106724A1 (en) | 2016-12-05 | 2018-06-14 | The Regents Of The University Of California | Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies |
KR20190104194A (ko) | 2017-01-07 | 2019-09-06 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여 |
WO2018140946A1 (en) | 2017-01-30 | 2018-08-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant virus vectors for the treatment of glycogen storage disease |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
US11788087B2 (en) | 2017-05-25 | 2023-10-17 | The Children's Medical Center Corporation | BCL11A guide delivery |
WO2019056015A2 (en) | 2017-09-18 | 2019-03-21 | Children's Hospital Medical Center | STRONG ISOLATOR AND ITS USES IN GENE ADMINISTRATION |
JP7427584B2 (ja) | 2017-10-13 | 2024-02-05 | セレクタ バイオサイエンシーズ インコーポレーテッド | 抗ウイルス導入ベクターigm応答を減弱化するための方法および組成物 |
EP3704250A1 (en) | 2017-11-03 | 2020-09-09 | InteRNA Technologies B.V. | Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
WO2019165436A1 (en) | 2018-02-26 | 2019-08-29 | Antolrx | Tolerogenic liposomes and methods of use thereof |
US11344008B1 (en) * | 2018-03-11 | 2022-05-31 | Hai Xing Chen | Production of human DNaseI in erythrocytes of transgenic non-human mammal using erythroid-specific promoter |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
JP2022524081A (ja) | 2019-03-08 | 2022-04-27 | オブシディアン セラピューティクス, インコーポレイテッド | 調整可能な制御のためのヒトカルボニックアンヒドラーゼ2組成物及び方法 |
US20200325241A1 (en) | 2019-04-11 | 2020-10-15 | Massachusetts Institute Of Technology | Novel chimeric antigen receptors and libraries |
CA3138525A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
EP3973065A1 (en) | 2019-05-23 | 2022-03-30 | Massachusetts Institute Of Technology | Ligand discovery and gene delivery via retroviral surface display |
US20200390718A1 (en) | 2019-05-28 | 2020-12-17 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
CN113046392B (zh) * | 2019-12-27 | 2023-04-07 | 深圳市禾沐基因生物技术有限责任公司 | 治疗β-球蛋白功能缺失的重组慢病毒载体及制备方法和应用 |
CA3217862A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
CA3225985A1 (en) | 2021-07-01 | 2023-01-05 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
KR20240035852A (ko) | 2021-07-19 | 2024-03-18 | 2세븐티 바이오, 인코포레이티드 | 벡터 제조 프로세스 |
WO2023019227A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
WO2023019229A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
WO2023047089A1 (en) | 2021-09-21 | 2023-03-30 | Oslo Universitetssykehus Hf | Binding proteins for terminal deoxynucleotidyl transferase (tdt) |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023114918A1 (en) | 2021-12-16 | 2023-06-22 | Ludwig Institute For Cancer Research Ltd | Antisense transfer vectors and methods of use thereof |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
CN114457119B (zh) * | 2022-04-11 | 2022-08-12 | 中吉智药(南京)生物技术有限公司 | 慢病毒载体在制备治疗β-地中海贫血药物中的应用 |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024050450A1 (en) | 2022-08-31 | 2024-03-07 | Gigamune, Inc. | Engineered enveloped vectors and methods of use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994023046A1 (en) * | 1993-04-07 | 1994-10-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
EP0783575B1 (en) * | 1994-09-19 | 1999-06-16 | Massachusetts Institute Of Technology | Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease |
WO1998017684A2 (en) * | 1996-10-25 | 1998-04-30 | Advanced Research & Technology Institute | Dna sequences encoding fusions of dna repair proteins and uses thereof |
US6531123B1 (en) * | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
US6136597A (en) * | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
AU1128400A (en) * | 1998-10-22 | 2000-05-08 | Medical College Of Georgia Institute, Inc. | Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors |
WO2002083080A2 (en) | 2001-04-17 | 2002-10-24 | Genetix Pharmaceuticals, Inc. | Method of treating arthritis using lentiviral vectors in gene therapy |
US20040033604A1 (en) | 2001-04-20 | 2004-02-19 | Gary Kobinger | Recombinant lentiviral vectors pseudotyped in envelopes containing filovirus binding domains |
US20030039636A1 (en) * | 2001-05-01 | 2003-02-27 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (SIN) lentiviral vectors |
IL161229A0 (en) * | 2001-10-02 | 2004-09-27 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications. |
ATE474460T1 (de) | 2002-12-13 | 2010-08-15 | Genetix Pharmaceuticals Inc | Therapeutische retrovirus-vektoren für gentherapie |
-
2003
- 2003-12-11 AT AT03813391T patent/ATE474460T1/de not_active IP Right Cessation
- 2003-12-11 DE DE60333487T patent/DE60333487D1/de not_active Expired - Lifetime
- 2003-12-11 ES ES03813391T patent/ES2348868T3/es not_active Expired - Lifetime
- 2003-12-11 AU AU2003296958A patent/AU2003296958A1/en not_active Abandoned
- 2003-12-11 WO PCT/US2003/039526 patent/WO2004054512A2/en not_active Application Discontinuation
- 2003-12-11 EP EP03813391A patent/EP1581056B1/en not_active Expired - Lifetime
-
2005
- 2005-06-09 US US11/150,785 patent/US7901671B2/en not_active Expired - Lifetime
-
2006
- 2006-04-04 HK HK06104166.4A patent/HK1082379A1/xx not_active IP Right Cessation
-
2010
- 2010-10-11 CY CY20101100906T patent/CY1112327T1/el unknown
- 2010-12-22 US US12/976,078 patent/US20110274669A1/en not_active Abandoned
-
2011
- 2011-09-23 US US13/242,815 patent/US9068199B2/en not_active Expired - Lifetime
-
2015
- 2015-04-29 US US14/700,021 patent/US10105451B2/en not_active Expired - Lifetime
-
2018
- 2018-09-13 US US16/130,845 patent/US10632212B2/en not_active Expired - Lifetime
-
2020
- 2020-03-16 US US16/820,066 patent/US11701435B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1581056A4 (en) | 2007-01-17 |
US7901671B2 (en) | 2011-03-08 |
US11701435B2 (en) | 2023-07-18 |
WO2004054512A2 (en) | 2004-07-01 |
US20160022839A1 (en) | 2016-01-28 |
HK1082379A1 (en) | 2006-06-09 |
WO2004054512A3 (en) | 2005-01-06 |
US20120009161A1 (en) | 2012-01-12 |
DE60333487D1 (de) | 2010-09-02 |
US20200368370A1 (en) | 2020-11-26 |
EP1581056A2 (en) | 2005-10-05 |
US20110274669A1 (en) | 2011-11-10 |
ES2348868T3 (es) | 2010-12-16 |
AU2003296958A1 (en) | 2004-07-09 |
US10105451B2 (en) | 2018-10-23 |
US20190038775A1 (en) | 2019-02-07 |
US10632212B2 (en) | 2020-04-28 |
ATE474460T1 (de) | 2010-08-15 |
AU2003296958A8 (en) | 2004-07-09 |
US20060057725A1 (en) | 2006-03-16 |
EP1581056B1 (en) | 2010-07-21 |
US9068199B2 (en) | 2015-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112327T1 (el) | Θεραπευτικοι ρετροϊικοι φορεις για γονιδιακη θεραπεια | |
Zhang et al. | Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity | |
ATE368731T1 (de) | Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen | |
EP1491093A3 (en) | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof | |
TW200510306A (en) | Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them | |
MX2007004551A (es) | Compuestos tiadiazol y metodos de uso. | |
ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
DK1226233T3 (da) | Multipotente voksne stamceller og fremgangsmåder til isolering heraf | |
WO2006092668A3 (en) | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same | |
ATE286053T1 (de) | Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung | |
DE60231439D1 (de) | Mitotische kinesinhemmer | |
DE60324449D1 (de) | Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie | |
NO20081349L (no) | Pyrrolopyrimidinderivater som Syk-inhibitorer | |
PL397846A1 (pl) | Leczenie zaburzeń związanych z TNFα | |
MXPA02007099A (es) | Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina. | |
WO2003016499A3 (en) | Combinatorial methods for inducing cancer cell death | |
DE50007706D1 (de) | Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ | |
DK1274464T3 (da) | Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm | |
Khajeniazi et al. | Synergistic induction of cardiomyocyte differentiation from human bone marrow mesenchymal stem cells by interleukin 1β and 5-azacytidine | |
PT1147103E (pt) | Fenantridina-n-oxidos com actividade inibitoria de pde-iv | |
ATE321566T1 (de) | Verwendung von long pentraxin ptx3 für die behandlung von infertilität bei frauen | |
DK1147088T3 (da) | 6-arylphenanthridiner med PDE-IV-inhiberende aktivitet | |
NO20055517L (no) | 4-,6-O 7-hydroksyindoler med N-oksidgrupper og anvendelse av disse som terapeutiske midler | |
ZA200609220B (en) | Method of treating dry eye disorders and uveitis | |
ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 |